Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rimactal INH
- Development stage
- Phase 4
- Lead developer
- Amneal Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rimactal INH is a fixed-dose combination antibiotic therapy containing rifampicin and isoniazid, developed and marketed by Global Pharmaceuticals in Pakistan. It is indicated for the treatment and prevention of tuberculosis (TB) and other susceptible bacterial infections. Rifampicin, a rifamycin derivative, inhibits bacterial DNA-directed RNA polymerase, thereby blocking RNA synthesis. Isoniazid is a prodrug that, once activated by the bacterial enzyme KatG, inhibits the synthesis of mycolic acids, which are essential components of the mycobacterial cell wall. This dual-action approach targets both actively dividing and dormant *Mycobacterium tuberculosis* bacilli.
- Brand names
- Rimactal INH
- Other names
- rifampicin + isoniazid
02
Targets
rpoB (DNA-directed RNA polymerase subunit beta)InhARNAP (Bacterial dna-dependent RNA polymerase)
Beyond the preview
Go deeper on Rimactal INH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rimactal INH.